**Supplementary Table 2.** Details of association studies pertaining to specific genes/variants.  In the “Key genes or alleles studied” column, significant genes with specific alleles are noted; for non-significant alleles, the gene is given. rs IDs (dbSNP) or other identifiers are given when available.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Description of cases and controls** | **Population of studies** | **Key gene(s) or allele(s) studied** | **Specific results** | **PMID** |
| Cases: 37 cases of probable SARS-CoV-1; 28 fever patients later excluded as probable SARS-CoV-2  Controls: 101 high-risk, non-infected healthcare workers who were exposed or potentially exposed to SARS-CoV-1 (control A); 190 normal healthy, unrelated individuals (control B) | Taiwan | Significant:  HLA-B\*4601  Non-significant:  HLA-B\*5401  HLA-DRB1 | When comparing only severe probable SARS cases with high-risk healthcare workers (control A), severity of SAR-CoV-1 was associated with HLA-B\*4601 (OR = 10.62 [CI, 2.80-40.26]; P=0.0008) | 12969506 |
| Cases: 90 patients with serologically confirmed SARS-CoV-1 infections  Controls: Class I allele group: 18,774, bone marrow donors; class II allele group: 250 bone marrow registrants | Hong Kong | Significant:  HLA-B\*0703  HLA-DRB1\*0301  HLA-B60  Non-significant:  HLA-B\*4601  HLA-DR  HLA-DQ | Susceptibility to SARS-CoV-1 was associated with HLA-B\*0703 (OR = 4.08 [CI, 2.03–8.18]; P = 0.00072) and (protective) with HLA-DRB1\*0301 (OR = 0.06 [CI, 0.01–0.47]; P=0.00008)  Co-inheritance of HLA-B\*0703 and HLA-B60 was more frequent (P=0.000000003) in SARS-CoV-1 patients versus controls | 15243926 |
| Cases: 168 SARS-CoV-1 patients  Controls: 328 healthy volunteers | Hong Kong | Non-significant:  *ACE2* | SARS-CoV-1 outcome was not significantly associated with *ACE2* polymorphisms | 15331509 |
| Cases: 44 SARS-CoV-1 patients, subdivided into hypoxemic (22) and non-hypoxemic (22) groups  Controls: 103 hospital staff members who had indirect or direct contact with a SARS-CoV-1 patient; 50 additional controls with no contact history | Vietnam | Significant:  *ACE* D allele | Risk of hypoxemia in SARS-CoV-1 patients was associated with the number of *ACE* D alleles (OR =  3.04 [CI, 1.15–8.02]; P = 0.025) | 15381116 |
| Cases: 44 SARS-CoV-1 patients, subdivided into hypoxemic (22) and non-hypoxemic (22) groups  Controls: 103 hospital staff members who had indirect or direct contact with a SARS-CoV-1 patient; 50 additional controls with no contact history | Vietnam | Significant:  *OAS1* rs3741981 and rs2660  *MX1* rs2071430  Non-significant:  *PKR* | SARS-CoV-1 susceptibility (cases versus controls with contact history) was associated with *OAS1* rs3741981 status (OR = 2.68 [CI, 1.17–6.15]; P = 0.0178)  SARS-CoV-1 susceptibility (cases versus controls with contact history) was associated with *OAS1* rs3741981 status (P  = 0.0090)  SARS-CoV-1 susceptibility (infected versus uninfected) was associated with *OAS1* rs3741981 status (P  = 0.0156)  SARS-CoV-1 susceptibility  (infected versus uninfected) was associated with *OAS1* rs2660 status (P  = 0.0156)  Hypoxemia in SARS-CoV-1 infection was associated with *MX1* rs2071430 status (OR = 3.75 [CI, 1.08–10.7]; P = 0.0346) | 15766558 |
| Cases: 140 SARS-CoV-1 patients  Controls: 326 healthy volunteers | China | Non-significant:  *ACE* I/Dpolymorphism | SARS-CoV-1 susceptibility nor outcome were significantly associated with *ACE* I/D polymorphism status | 15819995 |
| Cases: 569 SARS-CoV-1 patients  Controls: 1188 healthy individuals (blood donors from population) | Hong Kong | Significant:  *MBL* | SARS-CoV-1 susceptibility was associated with *MBL* YB haplotype status (heterozygosity or homozygosity), associated with low MBL serum levels (OR = 1.52 [CI, 1.22-1.90]; P <0.001)  SARS-CoV-1 susceptibility was associated with YA/YB haplotype status (OR = 1.53 [CI, 1.12-2.10]; P = 0.016)  SARS-CoV-1 susceptibility was associated with *XA/YB* haplotype status (OR = 1.81 [CI, 1.14-2.88]; P = 0.016) | 15838797 |
| Cases: 44 SARS-CoV-1 cases  Controls: 16 SARS-CoV-1 antibody-positive contacts; 87 antibody-negative contacts; 50 non-contacts | Vietnam | Non-significant:  *ACE2* | SARS-CoV-1 susceptibility was not significantly associated with ACE2 allele status | 15937940 |
| Cases: 352 SARS-CoV-1 patients  Controls: 392 healthy individuals | China | Significant:  *MBL* rs1800450 | SARS-CoV-1 susceptibility was associated with *MBL* rs1800450status (OR = 1.73 [CI, 1.25–2.39]; P = 0.00086)  SARS-CoV-1 infection was was associated with status of haplotype pairs with medium to low expression of *MBL* (OR = 1.67 [CI, 1.21–2.29]; P = 0.00187) | 16170752 |
| Cases: 180 unrelated SARS-CoV-1 patients (Home subgroup: 132 moderate SARS-CoV-1 patients who recovered without need for ventilation or intensive care; ICU subgroup: 26 severe SARS-CoV-1 patients who recovered with the need for ventilation or intensive care; Deceased subgroup: 22 deceased SARS-CoV-1 patients)  Controls: 200 blood donors | Hong Kong | Significant:  *FCGR2A* rs1801274  Non-significant:  *MBL* | SARS-CoV-1 ICU subgroup was associated with *FCGR2A* rs1801274 status (homozygosity) (OR=3.2 [CI: 1.1-9.1]; P = 0.03)  SARS-CoV-1 ICU and deceased subgroup without underlying illness was associated with *FCGR2A* rs1801274 status (P = 0.0388)  SARS-CoV-1 susceptibility (patients without underlying illness) was associated with *FCGR2A* rs1801274 status (P = 0.0419) | 16185324 |
| Cases: 154 SARS-CoV-1 patients with detectable SARS-CoV-1 by nasopharyngeal swab; 111 SARS-CoV-1 patients without detectable SARS-CoV-1  Controls: 94 randomly selected individuals from the general population | Taiwan | Significant:  *IL1A* rs1800587  *IL18* rs1946518  *FGL2* rs2075761  *RELB* rs2288918  Non-significant:  *ACE2*  *ACP5*  *ADAR*  *AIP*  *ANPEP*  *B2M*  *CAT*  *CCL5*  *CD209*  *CIITA*  *CXCL9*  *CYP17A1*  *EIF2AK3*  *EIF2S1*  *EIF4G1*  *ESR1*  *FN1*  *G6PD*  *GNB3*  *GPX1*  *GSS*  *HMOX1*  *IFNAR1*  *IFNAR2*  *IFNG*  *IFNGR1*  *IFNGR2*  *IL1B*  *IL1RN*  *IL4*  *IL6*  *IL10*  *IL10RB*  *IL12A*  *IL15*  *IRF1*  *IRF3*  *IRF7*  *MBL2*  *MX1*  *NFRKB*  *OAS1*  *PRDX2*  *PRKRA*  *PTGS2*  *RFX5*  *RNASEL*  *SERPINB3*  *SH2DIA*  *SLAMF1*  *SOCS1*  *SOCS3*  *SOD1*  *TBF*  *TFRC*  *TGFB1*  *TLR3*  *TLR4*  *TRAF6*  *WSX1* | SARS-CoV-1 infection (detectable) was associated with *IL1A* SNP rs1800587 (heterozygosity: OR = 10.2 [CI, 1.82-56.8); P = 0.08);  *IL18* rs1946518 (heterozygosity: OR = 4.47 [CI, 1.25-17.4]; homozygosity: OR = 10.6 [CI, 2.03-55.0]; P = 0.014)  *FGL2* rs2075761 (heterozygosity: OR = 4.0 [CI, 1.39-11.48]; P = 0.031)  *RELB* rs2288918 (homozygosity: OR = 7.20 [CI, 1.47-35.3); P = 0.034) | 16652313 |
| Cases: 66 confirmed SARS-CoV-1 patients  Controls: 64 close-contact healthy doctors and nurses working in the same hospital | China | Significant:  *OAS1* rs2660  *MX1* rs2071430 | SARS-CoV-1 susceptibility (protective) was associated with *OAS1* rs2660 (heterozygosity: OR = 0.42  [CI, 0.20-0.89]; P = 0.022; homozygosity: OR = 0.3 [CI, 0.09-0.97); P = 0.038)  SARS-CoV-1 susceptibility was associated with *MX1* rs2071430 status (OR = 3.06 [CI, 1.25-7.50]; P = 0.06) | 16824203 |
| Cases: 285 confirmed SARS-CoV-1 patients  (67 healthcare workers with SARS, 218 individuals from the community)  Controls: 380 healthy blood donors recruited prior to outbreak; 290 individuals chosen general outpatient clinics prior to outbreak, and with no signs or clinical history of infection; 172 seronegative healthcare workers exposed to SARS-CoV-1 | China | Significant:  *CLEC4M* VNTR | Overall, SARS-CoV-1 susceptibility (protective) was associated with *CLEC4M* VNTR (homozygosity: OR 0.706 [CI, 0.519-0.961]; P = 0.027)  SARS-CoV-1 susceptibility was associated (protective) with *CLEC4M* VNTR in non-healthcare workers in the community versus outpatient controls group (homozygosity: OR = 0.698 [CI: 0.490-0.993], P = 0.045)  SARS-CoV-1 susceptibility was associated with *CLEC4M* VNTR in healthcare worker patients versus controls (homozygotes: OR = 0.698 [CI, 0.303-0.950, P =0.031] | 16369534 |
| Cases: 20 SARS-CoV-1 seropositive healthcare workers  Controls: 80 control healthcare workers | Taiwan | Significant:  HLA-Cw\*0801  Non-significant:  HLA-A  HLA-B  HLA-DQB1  HLA-DRB1 | SARS-CoV-1 susceptibility was associated with HLA-Cw\*0801 status (OR = 4.4 [CI: 1.5-12.9; P=0.007) | 16455884 |
| Cases: 177 SARS-CoV-1 patients  Controls: 463 archived cord blood samples; 163 healthy individuals over the age of 70; 248 local university students | Hong Kong | Non-significant:  *CLEC4M* VNTR | SARS-CoV-1 susceptibility was not associated with *CLEC4M* VNTR status | 17534354 |
| Cases: 339 individuals with SARS-Cov-1 infection from Beijing community; 42 Beijing healthcare workers infected with SARS-CoV-1 infection; 60 individuals with SARS-CoV-1 infection from Tianjin  Controls: 227 random controls from Beijing community; 40 Beijing healthcare workers who had contact with SARS-CoV-1 patients; 129 disease-free controls from Tianjin | China | Non-significant:  *CLEC4M* VNTR | SARS-CoV-1 susceptibility was not associated with *CLEC4M* VNTR status | 17534355 |
| Hong Kong:  Cases: 495 Hong Kong Chinese patients with SARS-CoV-1 infection, subdivided into ‘death group’ (57 patients who died from SARS-CoV-1) and ‘survival group’ (438 patients who survived SARS-CoV-1 infection)  Controls: 578 healthy blood donors  Beijing:  Cases: 356 Beijing Chinese patients with SARS-CoV-1 (‘severe group’ consisted of 20 patients who required intensive care or died from SARS-CoV-1; ‘mild group’ consisted of 336 remaining patients)  Controls: 367 healthy individuals | Hong Kong and Beijing | Significant:  *CCL5* rs2107538  Non-significant:  *CCL5* (other polymorphism)  *CXCL10*  *CXCL9* | Hong Kong:  SARS-CoV-1 susceptibility was associated with *CCL5* rs2107538 status. (overall: OR = 2.80 [CI, 2.11-3.71]; P  < 0.0001; heterozygosity: OR = 3.28 [CI, 2.32-4.64]; P <0.0001); homozygosity: OR = 3.06 [CI, 1.47-6.39]; P < 0.0001)  Beijing:  SARS-CoV-1 outcome (admission to ICU or death) was associated with *CCL5* rs2107538 (heterozygosity: OR = 4.27 [CI, 1.64-11.1]; P = 0.011) | 17540042 |
| Cases: 817 patients SARS-CoV-1infections  Controls: 307 healthcare worker controls; 290 outpatient controls; 309 household control subjects unaffected by SARS | China | Significant:  *ICAM3*  rs2304237  Non-significant:  *FCER2* | Higher LDH and lower WBC in SARS-CoV-1 patients was associated with *ICAM3* rs2304237 homozygosity (LDH: OR = 4.31 [CI, 1.37-13.56] P = 0.0067; WBC: OR = 0.30 [CI, 0.10-0.89]; P = 0.022) | 17570115 |
| Cases: 152 SARS-CoV-1 patients  Controls: 198 blood donors from Hong Kong | China | Significant:  *CD14* rs2569190  Non-significant:  TLR2  TLR4 | Severity of SARS-CoV-1 infection was associated with CD14 rs2569190 (versus mild disease: OR = 2.74 [CI: 1.15-6.57], P = 0.029; versus controls: OR = 2.41 [CI, 1.05-5.54]; P = 0.04) | 17913858 |
| Cases: 75 SARS-CoV-1 patients  Controls: 41 healthcare workers who had come into contact with SARS-CoV-1 patients; 92 healthy controls | China | Significant:  *TNF*  (-204) polymorphism  rs1800630  Non-significant:  TNF (other polymorphisms) | SARS-CoV-1 susceptibility (protective) was associated  with *TNF* (-204) status (heterozygosity: OR = 0.95 [CI: 0.90-0.99,; P = 0.04)  Femoral head necrosis in SARS-CoV-1 patients was associated with *TNF* (-204)status (heterozygotes: OR = 5.33 [CI: 1.39-20.45]; P = 0.01; homozygotes: OR = 5.67 [CI: 2.74-11.71]; P = 0.04)  Femoral head necrosis in SARS-CoV-1 patients was associated with *TNF* rs1800630 (OR = 6.42 [CI, 1.53-26.88]; P = 0.01) | 18312678 |
| Cases: 115 SARS-CoV-1 patients  Controls: 141 non-infected close contacts with SARS-CoV-1; 155 healthy blood donors | China | Significant:  *IL12RB1*(+1664) polymorphism  Non-significant:  *IL12RB1* (other polymorphisms) | SARS-CoV-1 susceptibility was associated with *IL12RB1*(+1664)(heterozygosity: OR = 2.09 [CI, 1.90-7.16], P =0.020; homozygosity:(OR =  2.34 [CI: 1.79-13.37], P = 0.022) | 18478121 |
| Cases: 181 SARS-CoV-1 patients  Controls: 172 population controls | China | Non-significant:  *CLEC4M*  *FCER2*  *CLEC4G*  *CD209* | SARS-CoV-1 susceptibility was not associated with the C-type lectin gene cluster analyzed | 18697825 |
| Cases: 285 SARS-CoV-1 patients: 67 healthcare workers infected while working, 218 community patients  Controls: 380 healthy blood donors; 290 patients from general outpatient clinics with no clinical history of SARS-CoV-1; 172 healthcare workers who worked in SARS-CoV-1 wards; 309 household controls who lived with SARS-CoV-1 patients but who remained unaffected | China | Significant:  *CLEC4M* VNTR  Non-significant:  *IFNAR1*  *IFNB1*  *IFNG*  *IL1A*  *ILB*  *IL4*  *IL6*  *NOS2* | SARS-CoV-1 susceptibility (protective) was associated with *CLEC4M* VNTR (homozygosity: OR = 0.706 [CI: 0.519-0.961]; P =0.027)  In non-healthcare worker and and healthcare worker populations, SARS-CoV-1 susceptibility (protective) was associated with *CLEC4M* VNTR (homozygosity: OR = 0.649 [CI: 0.481-0.876], P = 0.005) | 18708672 |
| Beijing:  Cases: 272 SARS-CoV-1 patients from Beijing hospital  Controls: 232 healthy controls from Beijing  Guangzhou:  Cases: 104 SARS-CoV-1 patients from Guangzhou hospital  Controls: 291 healthy controls from Guangzhou | China | Non-significant:  *MASP2* | SARS-CoV-1 susceptibility was not associated with *MASP2* polymorphisms | 19405982 |
| Cases: 44 SARS-CoV-1 patients  Controls: 103 hospital staff members who had indirect or direct contact with a SARS-CoV-1 patient; 50 additional controls with no contact history | Vietnam | Significant:  HLA-DRB1\*1202  Non-significant:  HLA-DRB1\*1301  HLA-DRB1\*1302  HLA-DRB1\*1303 | SARS-CoV-1 susceptibility was associated with HLA-DRB1\*1202 (P = 0.042) | 19445991 |
| Cases: 100 SARS-CoV-1 patients  Compared genotypic data from cases with clinical data from 461 SAR-CoV-1 patients for parameter estimation | China | Significant:  *CXCL10* (−938AA)  *FLG2* (+158T/\*)  *HMOX1*(−497A/\*) (in relation to other variants) | SARS-CoV1 susceptibility (protective) was associated with *CXCL10*(−938AA) always increases resistance to SARS-CoV infection, and is always present with either *FLG2*(+158T/\*) (For those with this combination, β = 0.2839 [CI: 0.2467–0.3210], versus β = 0.3615 [CI: 0.3239–0.3990] for those without) or *HMOX1*(−497A/\*) (For those with this combination, β = 0.2763 [CI: 0.2391–0.3114], versus β = 0.3691 [CI: 0.3315–0.4067] for those without)  Susceptibility to SARS-CoV-1 is associated with *FLG2*(+158T/\*) unless present with CXCL10(−938AA)  For those with *FGL2*(+158T/\*) genotype only, β = 0.4432 [CI, 0.4060–0.4804]  For those with *HMOX1*(-497A/\*) genotype only, β = 0.3274 [CI, 0.2900–0.3648]  For those with a combination of *FLG2*(+158T/\*) and *HMOX1*(-497A/\*), β = 0.4308 [CI, 0.3937–0.4680] | 19590927 |
| Cases: 824 SARS-CoV-1 patients  Controls: 307 healthcare worker controls; 290 outpatient controls; 309 household control subjects unaffected by SARS-CoV-1 | China | Significant:  *CD209* rs4804803  ICAM3 rs2304237 | Lower LDH levels were associated with *CD209* rs4804803 status (OR = 0.36 [CI: 0.13-0.99] P =0.048)  Lower LDH levels were associated with ICAM3 rs2304237 status (OR = 1.97 [CI: 1.24-3.11] P =0.004)  High LDH levels contribute to poor clinical outcome | 20359516 |
| Cases: 817 SARS-CoV-1 patients  Controls: 422 control subjects  (989 of the total 1210 subjects were genetically unrelated) | China | Significant:  *MX1* rs2071430  Non-significant:  *MX1* (other polymorphism)  *OAS1* | After confounding effects such as age and sex were excluded, a significant association was found between *MX1* -88G>T (rs2071430) and decreased SARS susceptibility. (OR=0.58; 95% CI: 0.41-0.82, P=0.002)  After confounding effects were excluded, association between *MX1* -123C>A (rs17000900) and SARS susceptibility was found to be insignificant.  No significant association was found between *OAS1* SNPs rs1131454 and rs2660 and susceptibility to SARS-CoV infection. | 20462354 |
| Cases: 102 SARS-CoV-1 patients  Controls: 108 SARS-CoV-1 contacts | China | Non-significant:  HLA-DRB4\*01010101  HLA-B\*1502  HLA-DRB3\*030101 | After correction, SARS-CoV-1 susceptibility was not associated with the HLA alleles | 20864745 |
| Cases: 824 SARS-CoV-1 patients  Controls: 471 total control subjects (281 household contacts, 190 healthcare workers who worked in SARS-CoV-1 wards but remained disease-free) | China | Significant:  *CD209* rs4804803 | Lower LDH was associated with *CD209* rs4804803 (homozygosity: OR = 0.41 [CI, 0.20-0.86]; P = 0.014) | 20864747 |
| Guangzhou:  Cases: 67 SARS-CoV-1 patients from Guangzhou  Controls: 192 healthy controls  Beijing:  Cases: 624 SARS-CoV-1 patients from Beijing  Controls: 791 healthy controls  Healthcare workers:  Cases: 40 healthcare workers who had previously developed SARS-CoV-1  Controls: 122 healthcare workers who never developed SARS-CoV-1 | China | Significant:  *AHSG*  rs2248690  Non-significant:  *CYP4F3A*  *AHSG* (other polymorphism) | SARS-CoV-1 susceptibility was associated with *AHSG* rs2248690 (OR = 1.70 [CI, 1.37–2.09]; P < 0.001)  AHSG serum concentration was also associated with *AHSG* rs2248690 and *AHSG* serum concentrations in the control group. (P = 0.0001) | 21904596 |
| Cases: 56 SARS-CoV-1 positive healthcare workers  Controls: 41 SARS-CoV-1 negative healthcare workers | Taiwan | Significant:  HLA-Cw\*1502  Non-significant:  HLA-DR 0301  HLA-B\*4001  HLA-B\*4601  HLA-B\*1301  HLA-B\*5801  HLA-Cw\*0102  HLA-Cw\*0702  HLA-Cw\*0304  HLA-DR\*0901  HLA-DR\*1501  HLA-DR\*1202 | SARS-CoV-1 susceptibility (protective) was associated with HLA-Cw 1502 (OR=0.17 [CI, 0.04-0.81]; P = 0.01) | 21958371 |
| Cases: 176 SARS-CoV-1 patients  Controls: 18,774 blood donors | Hong Kong | Non-significant:  *HLA-A*  *HLA-B*  *HLA-DRB1* | SARS-CoV-1 susceptibility and outcome were not associated with *HLA* alleles | 24643938 |
| Beijing community:  Cases: 352 SARS-CoV-1 patients (20 severe) from one hospital  Controls: 392 healthy controls  Beijing healthcare worker:  Cases: 42 SARS-CoV-1 positive healthcare workers from one hospital  Controls: 40 healthcare workers from the same hospital who remained negative  Tianjin:  Cases: 60 patients with SARS-CoV-1 from one hospital  Controls: 129 healthy controls (85 blood donors and 44 negative healthcare workers)  Hong Kong:  Cases: 478 SARS-CoV-1 patients (49 of whom died)  Controls: 421 healthy blood donorts | China and Hong Kong | Significant:  *CCL2* rs1024611  *MBL* rs1800450 | SARS-CoV-1 susceptibility was associated with *CCL2* rs1024611 (homozygosity: OR= 1.48 [CI: 1.21-1.82]; P = 0.00016)  Susceptibility to SARS-CoV-1 was associated with *MBL* rs1800450 (OR = 1.79 [1.45-2.21]; P =4.9 x 10^-8)  Susceptibility to SARS-CoV-1 was associated with a combination of the polymorphisms (OR = 1.62 [CI: 1.40-1.88]; P = 1.3 x 10^-10) | 25818534 |
| Meta-analysis of 386 studies involving tuberculosis, SARS-CoV-1, RSV, influenza, and other respiratory diseases | Multiple studies | Significant:  *IL4* rs2070874 | Susceptibility to infection in a pooled respiratory disease modell was associated with *IL4* rs2070874 (OR = 1.66 [CI, 1.29–2.14]; P= 0.0000868) | 26524966 |
| Cases: 80 SARS-CoV-2 patients (56 with mild disease, 24 with severe disease)  Controls: N/A (comparison between mild and severe disease groups) | China | Significant:  *IFITM3* rs12252 | SARS-CoV-2 severity was associated with *IFITM3* rs12252 in an age-dependent manner  is associated with more severe disease in an age- dependent manner (OR = 6.37; P = 0.0093) | 32348495 |

Abbreviations: AHSG: alpha 2-HS glycoprotein; CI: 95% confidence interval; LDH: lactate-dehydrogenase; MBL: Mannose-binding lectin; MERS-CoV: middle east respiratory syndrome coronavirus; N/A: not applicable; OR: odds ratio; RSV: respiratory syncytial virus; SARS-CoV-1: severe acute respiratory syndrome coronavirus 1; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VNTR: variable number tandem repeat; WBC: white blood cell